Harnessing the power of human immunity1

LIBTAYO helps to restore the antitumor T-cell response1

LIBTAYO is a human, hinge-stabilized IgG4, high-affinity PD-1 monoclonal antibody developed using VelocImmune® technology. As a result of LIBTAYO's inhibition of the PD-1—PD-L1/PD-L2 signaling pathway, T-cell receptor signaling can be reactivated, restoring antitumor activity.1,2

LIBTAYO® (cemiplimab-rwlc) mechanism of action
  • PD-1, programmed death receptor-1; PD-L1, programmed death ligand 1; PD-L2, programmed death ligand 2.
Study design
  1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC.
  2. Burova E et al [published online March 6, 2017]. Mol Cancer Ther. 2017;16(5):861-870. doi:10.1158/1535-7163.MCT-16-0665.